Akademik Veri Yönetim Sistemi
The European Society of Clinical Pharmacy Symposium 2025, Grenoble, Fransa, 26 - 28 Kasım 2025, ss.80, (Özet Bildiri)
Background: In Parkinson’s disease, lifelong medication adherence is crucial due to the condition’s progressive nature. However, non adherence remains a common barrier to effective symptom management and quality of life, with reported rates ranging from 10 to 67%. (Malek & Grosset, 2014). Aim: This cross-sectional observational study aims to assess medi cation adherence and evaluate sociodemographic and clinical characteristics in patients with idiopathic Parkinson’s disease (PD) attending a tertiary Neurology Outpatient Clinic. Method: This prospective, observational, cross-sectional study was conducted over 3 months in the Movement Disorders Outpatient Clinic of Neurology Department of Istanbul University. Patients aged C 18 years with a confirmed diagnosis of idiopathic PD based on the United Kingdom Parkinson’s Disease Society Brain Bank criteria who had been receiving PD-specific treatment for C 6 months were enrolled. Data were collected by a pharmacist via a 25-item structured questionnaire and a review of medical records. Adherence was evaluated using the Medication Adherence Report Scale-5 (MARS-5) (Horne & Weinman, 2002). Statistical analysis was performed using SPSS version 30.0. Results: A total of 112 patients, who met the inclusion criteria, agreed to participate in the study, while 20 declined. Among partic ipants, 46.4% were aged 65 years or older, and 38.4% were female. A total of 37.5% reported having previously discontinued Parkinson’s treatment for various reasons, whereas 62.5% stated their treatment had been continuous. The proportion of patients experiencing Parkinson’s symptoms for five years or more was 77.7%. Regular physical exercise was reported by 42.0% of participants. Patients were taking an average of 4.5 medications daily (range: 1–15). The most frequently reported complaints were somnolence (19.0%) and insomnia (17.0%). In addition, hypertension (26%) and depression (20%) were the most frequently reported comorbidities. A majority (91.1%) of the patients reported difficulty in performing daily activ ities due to the severity of the disease. Medication adherence was assessed using the MARS-5 scale, with high adherence (score: 24–25) observed in 77.7% of the patients. Patients aged C 65 had the highest mean adherence score (24 ± 1.7). Conclusion: Medication adherence in idiopathic PD was found generally high, particularly in older adults and physically active individuals. However, low treatment adherence was observed in some of the patients. These findings highlight the influence of age and lifestyle on adherence and emphasize the essential role of clinical pharmacists in supporting long-term medication management through patient education, side effect monitoring, and adherence counseling.